Rights and permissions
About this article
Cite this article
Should CMS limit reimbursement to rate for off-label alternative?. Pharmacoecon. Outcomes News 637, 3 (2011). https://doi.org/10.2165/00151234-201106370-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106370-00009